Do you want to read an article? Please log in or register.
ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer
Lung, Respiratory and Thoracic CancerLymphoma
Related content
Lung Cancer
Molecular Diagnostic and Precision Medicine in Non-Small Cell Lung Cancer. An Update on the Treatment of the Most Important Actionable Oncogenic Driver Alterations.
1Department of Medical Oncology, University Hospital Basel, Basel, Switzerland.
Lung, Respiratory and Thoracic Cancer
Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer
N Engl J Med.
Drilon A, Oxnard GR, Tan DSW, Loong HHF, Johnson M, Gainor J, McCoach CE, Gautschi O, Besse B, Cho BC, Peled N, Weiss J, Kim YJ, Ohe Y, Nishio M, Park K, Patel J, Seto T, Sakamoto T, Rosen E, Shah MH, Barlesi F, Cassier PA, Bazhenova L, De Braud F, Garralda E, Velcheti V, Satouchi M, Ohashi K, Pennell NA, Reckamp KL, Dy GK, Wolf J, Solomon B, Falchook G, Ebata K, Nguyen M, Nair B, Zhu EY, Yang L, Huang X, Olek E, Rothenberg SM, Goto K, Subbiah V
doi: 10.1056/NEJMoa2005653.
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Detection of oligoprogressive disease in oncogene-addicted non-small cell lung cancer using PET/CT versus CT in patients receiving a tyrosine kinase inhibitor
Lung Cancer.
Ng TL, Morgan RL, Patil T, Barón AE, Smith DE, Ross Camidge D
doi: 10.1016/j.lungcan.
Lung, Respiratory and Thoracic Cancer
RNA-based analysis of ALK fusions in non-small cell lung cancer cases showing IHC/FISH discordance
doi: 10.1186/s12885-018-5070-6.
Lung, Respiratory and Thoracic Cancer
Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours
ESMO Open
Paz-Ares L, Barlesi F, Siena S, Ahn MJ, Drilon A, Conley A, Rolfo C, Wolf J, Seto T, Doebele R, Kapre A, Chen D, McCallum S, Osborne S, Demetri G
doi: 10.1016/j.esmoop.2021.100113
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Non-interventional LUME-BioNIS study of nintedanib plus docetaxel after chemotherapy in adenocarcinoma non-small cell lung cancer: A subgroup analysis in patients with prior immunotherapy
★ 1
Recommended by
Dr Wolf-Dieter Janthur, Faculty Member
Lung Cancer.
Reck M, Syrigos K, Miliauskas S, Zöchbauer-Müller S, Fischer JR, Buchner H, Kitzing T, Kaiser R, Radonjic D, Kerr K
doi: 10.1016/j.lungcan.2020.08.004.
Lung, Respiratory and Thoracic Cancer
Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations
Cancers (Basel)
König D, Savic Prince S, Rothschild SI
doi: 10.3390/cancers13040804
Lung, Respiratory and Thoracic Cancer
The evolving landscape of biomarker testing for non-small cell lung cancer in Europe
Lung Cancer
Kerr KM, Bibeau F, Thunnissen E, Botling J, Ryška A, Wolf J, Öhrling K, Burdon P, Malapelle U, Büttner R
doi: 10.1016/j.lungcan.2021.02.026
Lung, Respiratory and Thoracic Cancer
Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance
Lung Cancer.
Zugazagoitia J, Gómez-Rueda A, Jantus-Lewintre E, Isla D, Camps C, Ramos I, Trigo JM, Bernabé R, Juan-Vidal O, Sanchez-Torres JM, García-Campelo R, Provencio M, Felip E, de Castro J, Faull I, Lanman RB, Ponce-Aix S, Paz-Ares L, Garrido P
doi: 10.1016/j.lungcan.